Systemic therapy for locally advanced and metastatic non–small cell lung cancer: a review
KC Arbour, GJ Riely - Jama, 2019 - jamanetwork.com
Importance Non–small cell lung cancer remains the leading cause of cancer death in the
United States. Until the last decade, the 5-year overall survival rate for patients with …
United States. Until the last decade, the 5-year overall survival rate for patients with …
[HTML][HTML] Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer …
ACZ Gelatti, A Drilon, FC Santini - Lung cancer, 2019 - Elsevier
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …
Design, synthesis and anticancer evaluation of thieno [2, 3-d] pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers
SA Elmetwally, KF Saied, IH Eissa, EB Elkaeed - Bioorganic chemistry, 2019 - Elsevier
Deregulation of many kinases is directly linked to cancer development and the tyrosine
kinase family is one of the most important targets in current cancer therapy regimens. In this …
kinase family is one of the most important targets in current cancer therapy regimens. In this …
Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies
MJ Ahn, CM Tsai, FA Shepherd, L Bazhenova… - Cancer, 2019 - Wiley Online Library
Background Osimertinib is a third‐generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) that is selective for both EGFR‐TKI–sensitizing and T790M …
tyrosine kinase inhibitor (TKI) that is selective for both EGFR‐TKI–sensitizing and T790M …
Tissue and plasma EGFR mutation analysis in the FLAURA trial: Osimertinib versus Comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with …
JE Gray, I Okamoto, V Sriuranpong, J Vansteenkiste… - Clinical cancer …, 2019 - AACR
Purpose: To assess the utility of the cobas EGFR Mutation Test, with tissue and plasma, for
first-line osimertinib therapy for patients with EGFR-mutated (EGFR m; Ex19del and/or …
first-line osimertinib therapy for patients with EGFR-mutated (EGFR m; Ex19del and/or …
Emerging therapies for non-small cell lung cancer
Recent advances in the field of novel anticancer agents prolong patients' survival and show
a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the …
a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the …
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
Y Ohe, F Imamura, N Nogami, I Okamoto… - Japanese journal of …, 2019 - academic.oup.com
Background The FLAURA study was a multicenter, double-blind, Phase 3 study in which
patients with previously untreated epidermal growth factor receptor mutation-positive …
patients with previously untreated epidermal growth factor receptor mutation-positive …
Advances in targeted therapy and immunotherapy for non-small cell lung cancer based on accurate molecular typing
J Dong, B Li, D Lin, Q Zhou, D Huang - Frontiers in pharmacology, 2019 - frontiersin.org
The essence of precision medicine is to achieve the goal of “individualized treatment”
through genotyping of patients and targeted therapy. At present, the pathogenic genes of …
through genotyping of patients and targeted therapy. At present, the pathogenic genes of …
Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer
J Gao, HR Li, C Jin, JH Jiang, JY Ding - Clinical and Translational …, 2019 - Springer
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) represents a paradigm
shift in the treatment of non-small cell lung cancer (NSCLC) patients and has been the first …
shift in the treatment of non-small cell lung cancer (NSCLC) patients and has been the first …
[HTML][HTML] Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
NMA Wright, GD Goss - Translational Lung Cancer Research, 2019 - ncbi.nlm.nih.gov
Mutations in the epidermal growth factor receptor (EGFR) gene are the most common
targetable genomic drivers of non-small cell lung cancer (NSCLC), occurring in …
targetable genomic drivers of non-small cell lung cancer (NSCLC), occurring in …